Structure Therapeutics, Inc. Sponsored ADR ( (GPCR)) has released its Q3 earnings. Here is a breakdown of the information Structure Therapeutics, Inc. Sponsored ADR presented to its investors.

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...